Pubblicazioni

Approfondimenti generali
Sarcomi dei tessuti molli e GIST, Linee Guida AIOM, 2017. [Apri]
The ESMO / European Sarcoma Network Working Group. Soft Tissue and Visceral Sarcomas: ESMO Clinical Practice Guidelines [Apri]
The ESMO / European Sarcoma Network Working Group. Bone Sarcomas: ESMO Clinical Practice Guidelines [Apri]
The ESMO / European Sarcoma Network Working Group. Gastrointestinal Stromal Tumours: ESMO Clinical Practice Guidelines [Apri]
ClinicalTrial.gov. A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Judson I, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014;15:415-423 [Apri]
Demetri GD, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 2016;34:786-93 [Apri]
van der Graaf WT, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-1886 [Apri]
Schoffsky P, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387:1629-1637 [Apri]
Lorigan P, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:3144-3150 [Apri]
Tamborini E, et al. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. J Pathol. 2007 Jun;212(2):227-235 [Apri]